Kinfo
Abeona Therapeutics Inc. logo

Abeona Therapeutics Inc.

ABEONASDAQHealthcare·US · USD
$7.01
+0.03 (+0.43%)
Prices as of July 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap399.54M USD
Enterprise value252.73M USD
Trailing P/E7.23
Forward P/E23.95
PEG ratio0.29
Price / sales26.91
Price / book2.69
Profitability
Gross margin69.08%
Operating margin-264.14%
Profit margin454.86%
Return on assets-38.92%
Return on equity70.99%
Income (TTM)
Revenue14.54M USD
Gross profit-18.01M USD
EBITDA72.45M USD
Net income66.14M USD
Diluted EPS$0.95
Rev. growth (YoY)60.89%
Balance sheet
Total cash168.27M USD
Total debt23.17M USD
Debt / equity15.99
Current ratio5.89
Book value / share$2.55
Cash flow (TTM)
Operating cash flow-77.73M USD
Levered free cash flow-56.59M USD
Shares & price
Shares outstanding56.87M
Float36.62M
Held by institutions70.52%
Beta1.33
50-day MA$5.76
200-day MA$5.23
52-week high$7.54
52-week low$4.00
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Recent payments
  • 2000-03-31$23,164,062.50
Earnings (EPS)
DateEst.ActualSurprise2026-05-13-0.39-0.30+23.08%2026-03-17-0.37-0.37+0.00%2026-02-091.341.16−13.43%2026-01-231.611.87+16.15%2025-11-12-0.34-0.11+67.65%
About Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious genetic and rare diseases. Headquartered in Cleveland, Ohio, and founded in 1974, the company concentrates on advanced platforms such as adeno-associated virus (AAV) gene therapies and cell-based approaches targeting conditions with high unmet medical need. Abeona Therapeutics’ pipeline is oriented toward disorders where durable treatment effects from a single administration could transform patient outcomes, particularly in inherited metabolic and connective tissue diseases. Its work spans research, clinical development, and regulatory interactions to bring novel therapies through late-stage trials. Within the healthcare technology and pharmaceutical sectors, Abeona Therapeutics plays a specialized role at the intersection of gene therapy innovation and rare disease medicine, collaborating with academic centers, clinical investigators, and industry partners to advance its therapeutic candidates and support broader adoption of gene-based treatments in modern medicine.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Vishwas Seshadri M.B.A., Ph.D.
Employees
226
Headquarters
Cleveland, OH, United States

Frequently asked questions about Abeona Therapeutics Inc.